Highlights Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
1.330 ^USD	-1.48%		-3.62%	-10.74%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Highlights

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition	CI
06/10/25	Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program	CI
14/08/25	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/05/25	Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	CI
15/05/25	Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
19/12/24	Marker Therapeutics to Raise $16.1 Million in Private Placement	MT
19/12/24	Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma	CI
27/11/24	Marker Therapeutics Files $300 Million Mixed Shelf	MT
14/11/24	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $1.9M	MT
14/11/24	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/08/24	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
14/08/24	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $1.2M	MT
12/08/24	Marker Therapeutics Gets $2 Million Grant From National Institutes of Health	MT
15/05/24	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	MT
15/05/24	Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/03/24	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
22/01/24	Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	CI
08/01/24	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	CI
11/12/23	Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	CI
09/11/23	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	MT
09/11/23	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
11/09/23	Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	CI